Bayer’s Factor XIa lower bleeding saw more strokes in small trial

We present an update on the state of the factor XI competitive market, building upon our previous analysis of three factor XI inhibitors for prevention of venous thromboembolism in knee surgery patients. Recently Bayer published its first clinical data on its oral, once-daily factor XIa candidate asundexian.